Catalyst Pharmaceuticals Inc (CPRX)Healthcare | Biotechnology | Coral Gables, United States |
USD
|
Hot Take ↕ | Aug. 22, 2026, 6:06 a.m. UTC
The investment thesis for this biotech firm has completely evaporated due to a definitive corporate event: the company was acquired by Angelini Pharma for approximately $4.1 billion, resulting in the delisting of its shares from Nasdaq. With the stock trading flat at $31.49 since the announcement and no active trading volume or price discovery occurring, there is no viable short-term trade to execute. From a long-term perspective, the entity no longer exists as an independent public company; the business is now part of a larger portfolio, rendering any assessment of future growth, revenue trajectory, or competitive positioning moot for a public investor. Furthermore, the company has never paid a dividend, offering no income component to offset the total loss of liquidity and independence. |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.265 |
| Revenue per Share | 4.874 |
| Market Cap | 3,854,925,568 |
| Trailing P/E | 18.20 |
| Forward P/E | 9.90 |
| Beta | 0.74 |
| Profit Margins | 37.08% |
| Website | https://catalystpharma.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.50166905 |
| Address1 | 355 Alhambra Circle |
| Address2 | Suite 801 |
| All Time High | 32.56 |
| All Time Low | 0.37 |
| Ask | 35.91 |
| Ask Size | 100 |
| Audit Risk | 8 |
| Average Daily Volume10 Day | 2,596,397 |
| Average Volume | 2,547,424 |
| Average Volume10Days | 2,596,397 |
| Beta | 0.742 |
| Bid | 27.07 |
| Bid Size | 100 |
| Board Risk | 3 |
| Book Value | 8.288 |
| City | Coral Gables |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Currency | USD |
| Current Price | 31.49 |
| Current Ratio | 7.103 |
| Date Short Interest | 1,782,777,600 |
| Day High | 31.48 |
| Day Low | 31.47 |
| Debt To Equity | 0.265 |
| Earnings Growth | 0.111 |
| Earnings Quarterly Growth | 0.123 |
| Ebitda | 305,828,992 |
| Ebitda Margins | 0.51230997 |
| Enterprise To Ebitda | 10.138 |
| Enterprise To Revenue | 5.194 |
| Enterprise Value | 3,100,599,552 |
| Exchange | NGM |
| Exchange Timezone Name | UTC |
| Fifty Day Average | 31.3656 |
| Fifty Two Week High | 32.56 |
| Fifty Two Week Low | 19.05 |
| Financial Currency | USD |
| First Trade Date Epoch Utc | 1,784,122,200 |
| Float Shares | 115,583,952 |
| Forward Eps | 3.48 |
| Forward P E | 9.899184 |
| Free Cashflow | 171,809,872 |
| Full Time Employees | 182 |
| Fullday Price | 31.49 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.84036005 |
| Gross Profits | 501,657,984 |
| Held Percent Insiders | 0.05574 |
| Held Percent Institutions | 0.89997 |
| Implied Shares Outstanding | 122,417,458 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida. |
| Long Name | Catalyst Pharmaceuticals Inc |
| Market Cap | 3,854,925,568 |
| Max Age | 86,400 |
| Message Board Id | finmb_5103575 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | 221,323,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Number Of Analyst Opinions | 3 |
| Open | 31.47 |
| Operating Cashflow | 208,214,000 |
| Operating Margins | 0.49021 |
| Overall Risk | 5 |
| Payout Ratio | 0.0 |
| Phone | 305 420 3200 |
| Previous Close | 0.0 |
| Price Hint | 2 |
| Price To Book | 3.799469 |
| Price To Sales Trailing12 Months | 6.457616 |
| Profit Margins | 0.37075 |
| Quick Ratio | 6.701 |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Regular Market Day High | 31.48 |
| Regular Market Day Low | 31.47 |
| Regular Market Open | 31.47 |
| Regular Market Previous Close | 0.0 |
| Regular Market Volume | 505,384 |
| Return On Assets | 0.16268 |
| Return On Equity | 0.24496001 |
| Revenue Growth | 0.056 |
| Revenue Per Share | 4.874 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 4 |
| Shares Outstanding | 122,417,458 |
| Shares Percent Shares Out | 0.0641 |
| Shares Short | 7,845,889 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 8,189,325 |
| Short Name | Catalyst Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.0678 |
| Short Ratio | 4.11 |
| State | FL |
| Symbol | CPRX |
| Target High Price | 32.0 |
| Target Low Price | 31.5 |
| Target Mean Price | 31.66667 |
| Target Median Price | 31.5 |
| Time Zone Full Name | America/New_York |
| Time Zone Short Name | EDT |
| Total Cash | 755,859,008 |
| Total Cash Per Share | 6.176 |
| Total Debt | 2,681,000 |
| Total Revenue | 596,958,016 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | NaN |
| Trailing Eps | 1.73 |
| Trailing P E | 18.202312 |
| Trailing Peg Ratio | None |
| Two Hundred Day Average | 25.8999 |
| Underlying Symbol | CPRX |
| Uuid | 701,918ca-1fbf-3631-8a48-a246327450bb |
| Volume | 505,384 |
| Website | https://catalystpharma.com |
| Zip | 33,134 |